packagePatritumabDeruxtecan

patritumab deruxtecan

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Patritumab deruxtecan is an investigational antibody-drug conjugate being studied as an anticancer treatment. It is not yet approved; it remains in clinical development and is not authorised for routine use.

Unverified — written by glm-5.3-flash from general knowledge (no Wikidata entry found) and the WHO ATC classification; not checked by a person.

name:patritumab deruxtecan
ATC codes:L01FX36
DrugBank:DB21996

Metabolites

Deruxtecanderuxtecan493.5 g/mol (paper)
DXdDXdmolar mass unknown

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown

Contents

NameDescription
Deruxtecanmetabolite: deruxtecan
DXdmetabolite: DXd